Life Sciences Verification Program (LSVP)
Vetted-access program giving life-science researchers Claude Mythos, Opus, and Sonnet with more permissive biology safeguards.
Overview
Anthropic opened applications for the Life Sciences Verification Program on September 17, 2026, moving what had been a narrow early-access cohort into a broader beta for qualifying teams and institutions. The program gives verified life-science professionals access to Claude Mythos, Opus, and Sonnet with adjusted biology-related safeguards for work such as drug discovery, research biology, clinical development, and manufacturing that is otherwise blocked in generally available models; non-life-sciences safeguards stay in place. Access has two tiers: Standard Use, which covers most routine life-sciences work, extends to a team, and renews annually; and High-risk Use, an add-on for a single named project that renews every six months and, for now, applies to Opus 5 and Sonnet 5, with high-risk Mythos access still gated pending further U.S. government coordination. At launch LSVP is available through Anthropic's first-party API console and Claude for Enterprise/Team plans, but not for individual Pro/Max plans or BAA-enabled organizations. Anthropic developed the program in coordination with the U.S. government and had already onboarded dozens of organizations before opening broader applications.
This is a sourced directory entry. Features and capabilities are reported in the linked sources; this entry does not document independent Aymorphic testing.
Key features
- First program giving vetted external access to Claude Mythos with adjusted biology safeguards
- Two access tiers: Standard Use (team-wide, annual renewal) and High-risk Use (single named project, 6-month renewal)
- High-risk Use currently covers Opus 5 and Sonnet 5; high-risk Mythos access remains gated pending U.S. government coordination
- Developed in coordination with the U.S. government
- Available via first-party console and Claude for Enterprise/Team; not yet on Pro/Max plans or for BAA-enabled organizations
- Non-life-sciences safety restrictions remain in place under relaxed access
Use cases
- Drug discovery research requiring less restricted biology outputs
- Clinical development workflows
- Biomanufacturing process design
- Vetted academic and biodefense-adjacent life-sciences research
Pricing
unknown (application- and vetting-based access; no public pricing disclosed).
Pricing reflects the source record and may change. Confirm current terms with the provider.
Dates and sources
- Released
- 17 Sept 2026
- Record updated
- 23 Sept 2026
- Record last checked
- 23 Sept 2026